Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Earnings for Ocuphire Pharma, Inc. (OCUP)
Earnings in 2023 (TTM): $-9,974,000
According to Ocuphire Pharma, Inc.'s latest financial reports the company's current earnings (TTM) are $-9,974,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ocuphire Pharma, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-9,974,000 | $-9,986,000 |
| 2022 | $18.2 M | $17.89 M |
| 2021 | $-56,693,000 | $-56,534,000 |
| 2020 | $-24,620,000 | $-31,476,000 |
| 2019 | $-6,169,000 | $-7,510,000 |
| 2018 | $-14,368,530 | $-14,368,530 |
| 2017 | $-25,294,503 | $-25,294,503 |
| 2016 | $-9,307,345 | $-9,307,345 |
| 2015 | $-14,384,556 | $-14,384,556 |
| 2014 | $-18,521,601 | $-18,521,601 |
| 2013 | $-9,499,424 | $-9,499,424 |
| 2012 | $-6,226,670 | $-6,226,670 |
| 2011 | $-11,344,950 | $-11,344,950 |
| 2009 | $-6,387,428 | $-6,387,428 |
| 2008 | $-4,912,148 | $-4,912,148 |
| 2007 | $-4,304,005 | $-4,304,005 |
| 2006 | $-6,486,003 | $-6,486,003 |
| 2005 | $-6,349,540 | $-6,349,540 |